Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.

Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

Genital Chlamydia trachomatis infection is a significant public health burden; Professor of Pediatrics and Microbiology and ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...

Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...

Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...

It offers rapid, efficient and safe vaccines to protect animals and humans. The uniqueness of the technology lies in its ...

Good morning and welcome to Novavax' Third Quarter 2024 Financial Results and Operational Highlights Conference Call. All ...

Oct. 17, 2024 — With viral outbreaks spreading more quickly, faster responses and quicker development of new vaccines has become crucial. However, production of the mRNA used in vaccines is ...

S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella -naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and ...